Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Common Equity (2024 - 2026)

Maze Therapeutics' Common Equity history spans 3 years, with the latest figure at $341.7 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 16.99% to $341.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $341.7 million, a 16.99% increase, with the full-year FY2025 number at $355.0 million, up 214.07% from a year prior.
  • Common Equity hit $341.7 million in Q1 2026 for Maze Therapeutics, down from $355.0 million in the prior quarter.
  • Over the last five years, Common Equity for MAZE hit a ceiling of $379.4 million in Q3 2025 and a floor of -$403.7 million in Q1 2024.
  • Historically, Common Equity has averaged $41.0 million across 3 years, with a median of $262.2 million in 2025.
  • Biggest five-year swings in Common Equity: surged 233.35% in 2025 and later rose 16.99% in 2026.
  • Tracing MAZE's Common Equity over 3 years: stood at -$311.2 million in 2024, then surged by 214.07% to $355.0 million in 2025, then fell by 3.74% to $341.7 million in 2026.
  • Business Quant data shows Common Equity for MAZE at $341.7 million in Q1 2026, $355.0 million in Q4 2025, and $379.4 million in Q3 2025.